Given the data provided in the case, what is the revenue forecast for Repatha for 2018? Revenue is a function of number of patients treated x market share x price. What would be forecast if Amgen goes for the broader market (LDL patients) or the smaller market (FH patients)?

ADDITONAL INFORMATION

Exhibit 1: Amgen Financial Highlights (\$ in billions) Source: Amgen Annual Reports. Exhibit 2: Amgen's Largest Products (\$ in billions) Source: Amgen Annual Reports. Amgen was doing well in 2015. It was highly profitable: in 2014 , it had net income of $5.2 billion on revenues of $20.1 billion (see Exhibit 1). Over the prior two years, Amgen's revenue had grown at a CAGR of 7.8%. Profitability grew at an even faster rate, up 10.0%. Amgen's stock did exceptionally well, climbing from $85 per share at the start of 2013 to $160 at the start of 2015 . Market capitalization was over $120 billion. Amgen had six drugs with over $1 billion in revenues. The most important were Aranesp and Epogen, for anemia; Enbrel, for arthritis; and Neulasta, for febrile neutropenia, a condition associated with chemotherapy (see Exhibit 2). These key products accounted for the vast majority of Amgen's revenues. Amgen also had several products experiencing rapid revenue growth, including Prolia and Xgeva. The U.S. market was particularly important for Amgen, as it made up over 80% of all of Amgen's revenue. Exhibit 1: Amgen Financial Highlights (\$ in billions) Source: Amgen Annual Reports. Exhibit 2: Amgen's Largest Products (\$ in billions) Source: Amgen Annual Reports. Amgen was doing well in 2015. It was highly profitable: in 2014 , it had net income of $5.2 billion on revenues of $20.1 billion (see Exhibit 1). Over the prior two years, Amgen's revenue had grown at a CAGR of 7.8%. Profitability grew at an even faster rate, up 10.0%. Amgen's stock did exceptionally well, climbing from $85 per share at the start of 2013 to $160 at the start of 2015 . Market capitalization was over $120 billion. Amgen had six drugs with over $1 billion in revenues. The most important were Aranesp and Epogen, for anemia; Enbrel, for arthritis; and Neulasta, for febrile neutropenia, a condition associated with chemotherapy (see Exhibit 2). These key products accounted for the vast majority of Amgen's revenues. Amgen also had several products experiencing rapid revenue growth, including Prolia and Xgeva. The U.S. market was particularly important for Amgen, as it made up over 80% of all of Amgen's revenue